Research & Education

IASLC European Webinar Series - 2015/2016 - Treatment of ALK-Positive NSCLC

Tuesday, April 19, 2016 - 7 p.m. Central European Standard Time - Recording Available
Lucio Crino

Prof. Lucio Crinò, MD, PhD
Direttore S.C. di Oncologia Medica
Azienda Ospedaliera di Perugia, Italy

Name of Reviewer(s): 

              

Fred Hirsch, MD, PhD –Speakers Bureau/Advisory Board: Astrazeneca, Genentech, BMS, Lilly and Abbvie.

 

Name of Planner(s): 

 

Carlos Ferreira-Nothing to Disclose

Name of Activity: 

 

IASLC European Webinar Series - 2015/2016 - Treatment of ALK-Positive NSCLC

Date of Activity:

04/19/2016                  

Faculty/Speaker(s):

 

Lucio Crinò, MD, PhD-Nothing to Disclose
Direttore S.C. di Oncologia Medica; Azienda Ospedaliera di Perugia, Italy

Type of Activity: 

 

 Internet Live Course (Webinar)

 

Are there Commercial Supporters for this activity?

   No

If yes, please list:N/A

EML ALK inversion produces a new fusion protein kinase receptor active in 5-7% of lung adenocarcinomas. A number of small, oral molecules ALK TKI inhibitors have been developed recently. These agents have been shown to highly active and capable of substantial control of ALK driven disease. In this online educational presentation, we examine these data from recent c linical trials and address the role of ALK TKI inhibitors in current treatment paradigms.

Following the didactic presentation Dr. Crino will address questions from the audience. There will be ample opportunity for discussion and comments. Attendees may submit questions and comments to the faculty via Internet chat.

If you are interested in obtaining the CME Credits for these sessions you must complete the evaluation link provided to you after the activity. The Certificate of credit will be ready for you to print or save for your records.

CME Information:

Financial/Commercial Relationships & Conflicts of Interest DISCLOSURES

 

All individuals able to influence or control content of any CME certified activity that will be presented were required to complete a Financial Relationships/Conflicts of Interest Disclosure Form prior to the Internet Live Course.

“A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used on, patients that benefits the individual in any financial amount, and therefore may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected.”

This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/peer reviewers et. al. conflicts of interest  were identified, reviewed and resolved from all individuals involved in the development  or able to influence and control the content of this CME activity. IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.  Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from future IASLC CME activity presentations.

All commercial relationships and conflicts of interest identified were thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and/or an independent reviewer. COI was evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE

EML ALK inversion produces a new fusion protein kinase receptor active in 5-7% of lung adenocarcinomas. A number of small, oral molecules ALK TKI inhibitors have been developed recently.

These agents have been shown to highly active and capable of substantial control of ALK driven disease.

In this online educational presentation, we examine these data from recent clinical trials and address the role of ALK TKI inhibitors in current treatment paradigms.

Following the didactic presentation Dr. Crino will address questions from the audience. There will be ample opportunity for discussion and comments. Attendees may submit questions and comments to the faculty via Internet chat.

TARGET AUDIENCE

This CME live webinar was designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physician assistants.

LEARNING OBJECTIVES

TBD

DISCLAMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

TO RECEIVE CME CREDIT

Participants who complete a post-test along with an evaluation will receive 1 AMA PRA Category 1 CreditTM for each completed webinar. 

Upon completion of the electronic evaluation link the CME Certificate will be ready for you to print or save for your records. This information is used not only to evaluate the present activity, but also to plan for future programs.

Your opinion is very valuable! 

DOWNLOAD RECORDING

IASLC Financial/Commercial Relationships and Conflicts of interest policy

IASLC Invited speaker honoraria policy

Location Local time Time zone UTC offset
New York (U.S.A. - New York) Tuesday, April 19, 2016 at 1:00:00 PM EDT UTC-4 hours
Amsterdam (Netherlands) Tuesday, April 19, 2016 at 7:00:00 PM  CEST UTC+2 hours
Paris (France) Tuesday, April 19, 2016 at 7:00:00 PM CEST UTC+2 hours 
Barcelona (Spain) Tuesday, April 19, 2016 at 7:00:00 PM CEST UTC+2 hours
Frankfurt (Germany) Tuesday, April 19, 2016 at 7:00:00 PM CEST UTC+2 hours
Rome (Italy) Tuesday, April 19, 2016 at 7:00:00 PM CEST UTC+2 hours
London (United Kingdom) Tuesday, April 19, 2016 at 6:00:00 PM BST UTC+1 hour
Moscow (Russia) Tuesday, April 19, 2016 at 8:00:00 PM MSK UTC+3 hours
Budapest (Hungary) Tuesday, April 19, 2016 at 7:00:00 PM CEST UTC+2 hours
Vienna (Austria) Tuesday, April 19, 2016 at 7:00:00 PM CEST UTC+2 hours
Dublin (Ireland) Tuesday, April 19, 2016 at 6:00:00 PM IST UTC+1 hour
Prague (Czech Republic) Tuesday, April 19, 2016 at 7:00:00 PM CEST UTC+2 hours
Corresponding UTC (GMT) Tuesday, April 19, 2016 at 5:00:00 PM     

How to use the Time Zone Converter